Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Change in Inventory (2022 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Change in Inventory for 4 consecutive years, with $525000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Inventory fell 88.87% year-over-year to $525000.0, compared with a TTM value of $1.3 million through Dec 2025, down 85.29%, and an annual FY2025 reading of $1.3 million, down 85.29% over the prior year.
  • Change in Inventory was $525000.0 for Q4 2025 at Zevra Therapeutics, up from $194000.0 in the prior quarter.
  • Across five years, Change in Inventory topped out at $4.7 million in Q4 2024 and bottomed at -$241000.0 in Q3 2022.
  • Average Change in Inventory over 4 years is $655066.7, with a median of $194000.0 recorded in 2025.
  • The sharpest move saw Change in Inventory tumbled 112.03% in 2023, then soared 29568.75% in 2024.
  • Year by year, Change in Inventory stood at $133000.0 in 2022, then crashed by 112.03% to -$16000.0 in 2023, then skyrocketed by 29568.75% to $4.7 million in 2024, then crashed by 88.87% to $525000.0 in 2025.
  • Business Quant data shows Change in Inventory for ZVRA at $525000.0 in Q4 2025, $194000.0 in Q3 2025, and $381000.0 in Q2 2025.